Understanding Immune Checkpoint Inhibitors

Immune checkpoint inhibitors are a new class of cancer therapies that enhance T-cell function by blocking inhibitory signals that cancer cells use to suppress immune responses. These monoclonal antibodies target various cancers, including melanoma and lung cancer, helping improve patient outcomes significantly. There are four main classes of these inhibitors—anti-CTLA, anti-PD, anti-PD, and anti-LAG—with several drugs currently under development. However, the use of these therapies carries a risk of adverse events, with the likelihood varying based on the specific medication and the patient's unique treatment history.